Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

Breast Cancer Research and Treatment

Volumn 120, Issue 2, 2010, Pages 409-418

  Dunlap, Jennifer ^a   Le, Claudia ^b   Shukla, Arielle ^b   Patterson, Janice ^b   Presnell, Ajia ^b   Heinrich, Michael C ^b,c   Corless, Christopher L ^a,b   Troxell, Megan L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

AKT1; Breast carcinoma; Carcinoma in situ; Laser capture microdissection; Phosphatidylinositol 3 kinase (pik3ca)

Indexed keywords

HORMONE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN AKT1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER TISSUE; CONTROLLED STUDY; EARLY CANCER; EXON; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LASERS; MICRODISSECTION; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 77950691967     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0406-1     Document Type: Article

References (50)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M et al (1988) Genetic alterations during colorectaltumor development. N Engl J Med 319(9):525-532
2. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P et al (2003) Gene expression profiles of human breast cancer progression, Proc Natl Acad Sci. USA 100(10):5974-5979. doi: 10.1073/pnas.0931261100 (Pubitemid 36576916)
3. Reis-Filho JS, Lakhani SR (2003) The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 5(6):313-319. doi:10.1186/bcr650
4. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM (2004) Ductal Carcinoma in situ of the breast. N Engl J Med 350(14): 1430-1.441. doi : 1.0.1.056/NEJM.ra031301.
5. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR (2005) Molecular evolution of breast cancer. J Pathol 205(2):248-254. doi: 10.1002/path.1691
6. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al (2004) High frequency of mutations of the PIK3C A gene in human cancers. Science 304(5670):554. doi: 10.1126/science. 1096502 (Pubitemid 38541907)
7. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther 3(8):772-775 (Pubitemid 41351083)
8. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12):988-1004. doi:10.1038/nrd1902
9. Wymann MP, Marone R (2005) Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 17(2): 141-149. doi:10.1016/j.ceb.2005.02.011
10. Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3C.A oncogene in human cancers. Br J Cancer 94(4):455-459. doi:10.1038/sj.bjc.6602970 (Pubitemid 43289745)
11. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S et al (2006) Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 13(2):137-144. doi:10.2325/jbcs. 13.137
12. Dillon RL, White DE, Muller WJ (2007) The phosphatidyl inositol-3-kinase signaling network: implications for human breast cancer. Oncogene 26:1338-1345. doi: 10.1038/sj.onc. 1210202 (Pubitemid 46328463)
13. Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3(10):1221-1224 (Pubitemid 40268595)
14. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50):7455-7464. doi:10.I038/sj.onc. 1209085 (Pubitemid 41637985)
15. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554-2559. doi: 10.1158/0008-5472-CAN-04-3913 (Pubitemid 40490050)
16. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE et al (2007) PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13(12): 3577-3584. doi: 10.1158/1078-0432.CCR-06-1609 (Pubitemid 46955118)
17. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152):439-444. doi: 10.1038/nature05933 (Pubitemid 47123510)
18. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI et al (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11(8):2875-2878. doi: 10.1158/1078-0432.CCR-04-2142 (Pubitemid 40525186)
19. Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18:77-82. doi: 10.1097/0l.cco.0000 198021.99347.b9 (Pubitemid 43740454)
20. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21 ):7678-7681. doi: 10.1158/0008-5472.CAN-04-2933 (Pubitemid 39446895)
21. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW et al (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24(8): 1477-1480. doi: 10.1038/sj.onc. 1208304
22. Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z et al (2005) Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7(5):R609-R616. doi: 10.1186/ bcr1262
23. Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G et al (2006) PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 208(3):350-355. doi: 10.1002/path. 1908 (Pubitemid 43210521)
24. Li SY, Rong M, Grieu F, Iacopetta B (2006) PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 96(l):91-95. doi:10.1007/s 10549-005-9048-9050
25. Liang X, Lau QC, Salto-Tellez M, Putti TC, Loh M, Sukumar S (2006) Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese. Cancer Biol Ther 5(5):544-548 (Pubitemid 43765291)
26. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M et al (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13(20):6064-6069. doi: 10.1158/1078-0432.CCR-07-0266 (Pubitemid 350075063)
27. Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D et al (2008) PIK3CA cancer mutations display gender and tissue specificity patterns. Hum. Mutat 29(2):284-288 (Pubitemid 351240601)
28. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S (2007) Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13((2 Pt l.)):408-414. doi:10.11.58/1078-0432.CCR-06-0267 (Pubitemid 46225343)
29. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY (2008) PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients. Ann Surg Oncol 15(4):1064-1069. doi: 10.1245/s10434-007-9751-7
30. Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ et al (2008) PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 10(2):R27. doi:10.1186/bcr1984
31. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084-6091. doi: 10.1158/0008-5472. CAN-07-6854
32. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M et al (2008) AKT 1(E17K) in human solid tumours. Oncogene 27:5648-5650. doi: 10.1038/onc.2008.170
33. Kim MS, Jeong EG, Yoo NJ, Lee SH (2008) Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98(9): 1533-1535. doi: 10.1038/sj.bjc.6604212
34. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D et al (2008) Genetic predictors of MEK dependence in nonsmall cell lung cancer. Cancer Res 68(22):9375-9383. doi: 10.1158/0008-5472.CAN-08-2223
35. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American Society of Clinical Oncology/ College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 131(l):18-43 (Pubitemid 46174133)
36. Lasota J, vel Dobosz A, Wasag B, Wozniak A, Kraszewska E, Michej W et al (2007) Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors, Lab Invest 87(10): 1029-1041. doi: 10.1038/labinvest.3700628
37. Salvesen H, Carter S, Mannelqvist M, Dutt A, Getz G, Stefansson I et al (2009) Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 106(12):4834-4839. doi: 10.1073/pnas.080651.41.06
38. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J et al (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65(11):4562-4567. doi: 10.1158/0008-5472.CAN-04-4114 (Pubitemid 40740791)
39. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV et al (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65(23): 10992-11000. doi: 10.1158/0008-5472.CAN-05- 2612 (Pubitemid 41713369)
40. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M (2007) Cancerspecific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32(7):342-349. doi:10.1016/j.tibs.2007.05.005
41. Zhang H, Liu G, Dziubinski M, Yang Z, Ethier SP, Wu G (2008) Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat 112(2):217-227. doi:1.0.1.007/sl0549- 007-9847-9856
42. Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27(41):5486-5496. doi:10.1038/onc. 2008.244
43. Gymnopoulos M, Elsliger MA, Vogt PK (2007) Rare cancerspecific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104(13):5569-5574. doi:10.1073/pnas.0701.00 51.04 (Pubitemid 47175721)
44. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K et al (2008) PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res 68(19):81.27-81.36. doi: 10.1158/0008-5472.CAN-08-0755
45. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ et al (2006) PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12((20 Pt l)):5932-5935. doi: 10.1158/1078-0432. CCR-06-1375 (Pubitemid 44703751)
46. Velasco A, Bussaglia E, Paliares J, Dolcet X, Llobet D, Encinas M et al (2006) PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 37(11): 1465-1472. doi: 10.1016/j.humpath.2006. 05.007 (Pubitemid 44584324)
47. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11(1-2):32-50. doi:10.1016/j.drup.2007.11.003
48. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12): 1351-1356. doi:10.1038/nm. 1890
49. Garcia-Echeverria C, Sellers WR (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer, Oncogene 27(41):5511-5526. doi:10.1038/onc.2008.246
50. Crowder RJ, Ellis MJ (2005) Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway. Breast Cancer Res 7(5):212-21.4, doi: 10.1186/bcr1307